NEUROCRINE BIOSCIENCES INC - 8-K Filing
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, after acquiring approximately 88.9% of outstanding shares through a tender offer at $53 per share for an aggregate cash payment of about $2.9 billion. The company also entered into a $1.0 billion five-year senior secured revolving credit facility with JPMorgan Chase Bank on May 14, 2026. (Items: 1.01 Entry into a Material Definitive Agreement, 2.03 of this Current Report on Form 8-K (this “Report”) is incorporated by reference into this Item 1, 2.01 Completion of Acquisition or Disposition of Assets, 7.01 Regulation FD Disclosure)
Tickers: $NBIX